SCHEMBL2505658

SCHEMBL2505658

COc1cccc(C(=C(C)C(=O)O)C(F)(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.54
CES1 P23141 1/20 0.54
PARP1 P09874 1/20 0.51
NPC1 O15118 6/20 0.50
RAB9A P51151 6/20 0.50
SMN1; SMN2 Q16637 1/20 0.48
TSHR P16473 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
ALDH1A1 P00352 2/20 0.46
MAOB P27338 2/20 0.46
KCNK3 O14649 1/20 0.46
KCNK9 Q9NPC2 1/20 0.46
LMNA P02545 2/20 0.46
ABCG2 Q9UNQ0 1/20 0.44
NLRP3 Q96P20 1/20 0.44
KDM4E B2RXH2 1/20 0.44
HTT P42858 1/20 0.44
ESR1 P03372 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2505653 1.00 CES2 (0.54) CES2CES1PARP1NPC1RAB9A
SCHEMBL6299542 0.81 CES2 (0.61) CES2CES1PARP1NPC1RAB9A
SCHEMBL562773 0.79 CES1 (0.52) CES2CES1PARP1NPC1RAB9A
SCHEMBL8055824 0.79 CES2 (0.57) CES2RAB9ANPSR1MEN1KMT2A
SCHEMBL8055819 0.79 CES2 (0.57) CES2RAB9ANPSR1MEN1KMT2A
SCHEMBL8055817 0.79 CES2 (0.57) CES2RAB9ANPSR1MEN1KMT2A
SCHEMBL2500212 0.78 CES1 (0.65) CES2CES1PARP1NPC1RAB9A
SCHEMBL30214744 0.78 CES1 (0.65) CES2CES1PARP1NPC1RAB9A
Trifluoroacetic Acid SCHEMBL28214522 0.76 PARP1 (0.78) CES2CES1PARP1NPC1RAB9A
1,3-Dimethoxybenzene SCHEMBL11452224 0.76 LMNA (0.58) CES2CES1PARP1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 US disclosed